Top Markets
#1 Black Phoenix Black Phoenix +354.71%
#2 Glidr Glidr +84.34%
#3 OpenEden OpenEden +71.47%
#4 Gold Park Gold Park +68.84%
#5 Akedo Akedo +55.26%
#6 BasedHype BasedHype +26.51%
#7 Cryptopia Cryptopia +21.54%
#8 Humanity Humanity +20.22%
#9 Avantis Avantis +19.35%
#10 Ether.fi Ether.fi +17.25%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
ObsEva S.A. ObsEva S.A.

ObsEva S.A.

OBSN
Rank in Stocks #40302
ObsEva S.A. is a biopharmaceutical company focused on developing and... ObsEva S.A. is a biopharmaceutical company focused on developing and commercializing groundbreaking therapies for women facing challenges in reproductive health and pregnancy. Its product pipeline includes Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist currently in Phase III clinical trials. Linzagolix is being evaluated for its efficacy in treating pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The firm is also progressing with Ebopiprant, an oral and selective prostaglandin F2a (PGF2a) receptor antagonist, which is in Phase II clinical trials as a once-daily treatment for preterm labor occurring between 24 and 34 weeks of gestational age. Additionally, ObsEva is developing Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical trials, aimed at enhancing clinical pregnancy and live birth rates for women undergoing in vitro fertilization. ObsEva S.A. was founded in 2012 and maintains its headquarters in Geneva, Switzerland.
Share Price
$0.00156067
Last synced: 2024-05-03
Market Cap
$182.87K
Change (1 day)
-72.69%
Change (1 year)
0.00%
Country
CH
Trade ObsEva S.A. (OBSN)

Category

Healthcare
P/E ratio for ObsEva S.A. (OBSN)
P/E ratio as of 2026 TTM: 0
According to ObsEva S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for ObsEva S.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.